A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma

Stopped The study was terminated early due to Sponsor decision, the decision to terminate was not based on any safety concerns.

Conditions

• Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)

Interventions

• DRUG: ASTX660
• DRUG: ASTX660
• DRUG: ASTX660

Sponsor

Otsuka Pharmaceutical Co., Ltd.